P101. Quality of Life in Adult Women with Turner Syndrome

Egle Vaiciuliene (LT), Ruta Kriksciuniene (LT), Lina Lasaite (LT), Birute Zilaitiene (LT), Rasa Verkauskiene (LT)

[Vaiciuliene] Lithuanian University of Health Sciences, Medical Academy, Department of Endocrinology, [Kriksciuniene] Lithuanian University of Health Sciences, Medical Academy, Department of Endocrinology, [Lasaite] Lithuanian University of Health Sciences, Medical Academy, Institute of Endocrinology, [Zilaitiene] Lithuanian University of Health Sciences, Medical Academy, Institute of Endocrinology, [Verkauskiene] Lithuanian University of Health Sciences, Medical Academy, Institute of Endocrinology

Introduction: The aim of medical care and therapy should focus not only on the patient‘s physical health, but also on quality of life. Scientific data on quality of life in patients with Turner syndrome (TS) is rather few and controversial. The aim of the study was to analyze quality of life in adult women with Turner syndrome. Patients and methods: A total of 65 women with genetically confirmed TS (age 30.2±9.0 years) and 65 age-matched healthy women (age 29.2±7.1 years) were recruited for the study. Patients with TS were stratified by duration of growth hormone (GH) replacement therapy into three groups: no GH therapy at all, GH therapy for shorter than 5 years and GH therapy for longer than 5 years. Average duration of GH replacement therapy in all TS patients was 4.1±3.7 years. Quality of life (physical, psychological, social and environmental domains) was evaluated by generic quality of life questionnaire (WHO Brief Quality of Life Questionnaire, WHO QoL). Concentrations of Thyroid - stimulating hormone (TSH), Free thyroxine (FT4), Testosterone (T) were measured in TS patients for evaluating possible correlations between hormone levels and quality of life. Results: Patients with TS were of a significantly shorter stature than age-matched control women (151.9±6.8 cm vs. 167.4±5.9 cm, p < 0.001). In quality of life, evaluations of physical (15.7 ± 1.5 vs. 16.3 ± 1.6, p=0.014), psychological (14.4 ± 1.8 vs. 15.4 ± 1.4, p=0.001) and social (14.6 ± 2.0 vs. 15.8 ± 1.9, p < 0.001) subscales were significantly lower (meaning worse quality of life) in women with TS than in healthy age-matched women. Patients with longer duration of GH replacement therapy had significantly better evaluation in environment domain (15.1±1.1 vs 15.7±1.1 vs 16.0±0.8, p=0.041), but not in physical, psychological and social domains. Significant correlations in women with TS were found between thyroid stimulating hormone concentration and psychological domain of quality of life (r=-0.288, p=0.026), between testosterone concentration and psychological domain (r=0.273, p=0.037) and between free thyroxin concentration and physical domain (r=0.301, p=0.019). In conclusion, adult women with Turner syndrome have shorter stature and worse quality of life (with the impairments in physical, psychological and social aspects) in comparison to age-matched healthy women. Different aspects of quality of life possibly may be related to the hormonal state of the patients.